NCT04594954 is a NA clinical trial of Diet in Non-Alcoholic Fatty Liver Disease, sponsored by Institute of Liver and Biliary Sciences, India.

Who is sponsoring NCT04594954?

NCT04594954 is sponsored by Institute of Liver and Biliary Sciences, India.

What drugs are being tested in NCT04594954?

Interventions in NCT04594954: Diet, FMT, Physical Activity.

What condition does NCT04594954 study?

NCT04594954 studies Non-Alcoholic Fatty Liver Disease.

Is NCT04594954 still recruiting?

NCT04594954 is currently status unknown. Last updated 16 February 2021.

Last reviewed 2021-02-16 · How we verify

NCT04594954

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effects of Fecal Microbiota Transplantation on Weight in Obese Patients With Non-alcoholic Fatty Liver Disease

Status unknown NA Last updated 16 February 2021

What this trial tests

NA trial testing Diet in Non-Alcoholic Fatty Liver Disease in 110 participants. Status unknown.

Timeline

15 October 2020

Primary endpoint
30 September 2021

30 September 2021

Quick facts

Lead sponsor	Institute of Liver and Biliary Sciences, India
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	110
Start date	15 October 2020
Primary completion	30 September 2021
Estimated completion	30 September 2021
Sites	1 location across India

Drugs / interventions tested

Diet
FMT — full drug profile →
Physical Activity

Conditions studied

Non-Alcoholic Fatty Liver Disease — all drugs for Non-Alcoholic Fatty Liver Disease →

Sponsor

Institute of Liver and Biliary Sciences, India

Who can join

Adults 18 to 55, any sex, with Non-Alcoholic Fatty Liver Disease. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The worldwide impact of obesity suggests an urgent need for solutions to decrease its burden on modern society. It has been generally understood that obesity is caused by a simple imbalance in the intake of energy in the form of food compared with the expenditure of energy by the body the human microbiota consists of a wide variety of microorganisms, including bacteria, archaea, fungi, viruses, protozoans and yeast. These organisms colonize both the exterior and interior of the human body in numbers that are equivalent to those of human cells of their host. Current research has identified numerous physiological and psycho-modulatory functions of the gut microbiota, including digesting food, stimulating cell growth, strengthening the immune system, preventing allergies and diseases, and impacting emotion. The gut microbiota can contribute to host physiology through metabolite production, such as short-chain fatty acids (SCFAs), which can modulate the intestinal barrier and inflammation 9.Dysbiosis of the gut microbiota, defined as a decrease in commensal bacteria levels and diversity, has been linked to diseases such as stomach/colon/liver cancer 2, obesity 9,inflammatory bowel disease (IBD) and anxiety.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Gut microbiota modulation in patients with non-alcoholic fatty liver disease: Effects of current treatments and future strategies.
Maestri M, Santopaolo F, Pompili M, Gasbarrini A, et al · · 2023 · cited 52× · PMID 36875849 · DOI 10.3389/fnut.2023.1110536
Gut-Liver-Pancreas Axis Crosstalk in Health and Disease: From the Role of Microbial Metabolites to Innovative Microbiota Manipulating Strategies.
Marroncini G, Naldi L, Martinelli S, Amedei A. · · 2024 · cited 24× · PMID 39061972 · DOI 10.3390/biomedicines12071398
Pathophysiological Mechanisms in Non-Alcoholic Fatty Liver Disease: From Drivers to Targets.
Santos-Laso A, Gutiérrez-Larrañaga M, Alonso-Peña M, Medina JM, et al · · 2021 · cited 14× · PMID 35052726 · DOI 10.3390/biomedicines10010046
Faecal Microbiota Transplantation, Paving the Way to Treat Non-Alcoholic Fatty Liver Disease.
Del Barrio M, Lavín L, Santos-Laso Á, Arias-Loste MT, et al · · 2023 · cited 13× · PMID 37047094 · DOI 10.3390/ijms24076123
Over-feeding the gut microbiome: A scoping review on health implications and therapeutic perspectives.
Barone M, D'Amico F, Fabbrini M, Rampelli S, et al · · 2021 · cited 12× · PMID 34887627 · DOI 10.3748/wjg.v27.i41.7041
Targeting the Adipose Tissue-Liver-Gut Microbiota Crosstalk to Cure MASLD.
Gabbia D, De Martin S. · · 2023 · cited 10× · PMID 38132297 · DOI 10.3390/biology12121471
The Roles of Myeloid Cells in Aging-related Liver Diseases.
Yao J, Li Y, Wang H. · · 2023 · cited 9× · PMID 37056921 · DOI 10.7150/ijbs.82352
Gut microbiome and liver diseases.
Xu J, Chen N, Li Z, Liu Y. · · 2025 · cited 6× · PMID 40242515 · DOI 10.1016/j.fmre.2024.09.007

Verify or expand the search:

Other trials of Diet

Trials testing the same drug.

NCT07533513 — Effects and Mechanisms of Dietary Carbohydrate Intake and Quality on Glucose and Lipid Metabolism · NA · not yet recruiting
NCT07457827 — Effect of Low-Carbohydrate Versus Balanced Diets on Anthropometric Blood Pressure, ApoB, and hsCRP in Healthy Adults · NA · not yet recruiting
NCT07388589 — Soluble and Osmotic Fibre (SOLOS) Diet for Constipation · not yet recruiting
NCT07289672 — Food Limitations In Crohn's Disease and Ulcerative coliTis · NA · not yet recruiting
NCT07262112 — Efficacy of Resistance Exercise and an Anti-Inflammatory Diet on Pain, Disease Activity, Functional Status, and Quality · NA · not yet recruiting

Other recruiting trials for Non-Alcoholic Fatty Liver Disease

Currently open trials in the same condition.

NCT07403604 — Effect of Insulin Lowering on Lipogenesis · Phase 1 · recruiting
NCT07294963 — Impact of Lifestyle Interventions on Cognitive Decline in Non-alcoholic Fatty Liver Disease · NA · recruiting
NCT07130318 — Mediterranean Diet in Familial Mediterranean Fever: Is Fatty Liver Affected by Addition of Aerobic Exercise · NA · recruiting
NCT06355310 — Mechanisms of SGLT2 Inhibition in Pediatric Steatotic Liver Disease · Phase 2 · recruiting
NCT06863376 — Evaluating the Safety and Efficacy of Carbocisteine in the Treatment of Nonalcoholic Fatty Liver Disease Patients · Phase 2 · recruiting

Other Institute of Liver and Biliary Sciences, India trials

Trials by the same sponsor.

NCT07480005 — To Revisit the Yield of Staging Laparoscopy in Hepatopancreatobiliary Malignancies · recruiting
NCT07480057 — Assessment of Changes in Bone Mineral Metabolism After Liver Transplantation by Bone Mineral Densitometry · recruiting
NCT07465471 — Carvedilol and Midodrine Versus Carvedilol Alone in Preventing Early Rebleed in Patients With Cirrhosis. · NA · not yet recruiting
NCT07433881 — Serosurvey of HAV Immunity and Single-dose Vaccine Immunogenicity Among Patients With Cirrhosis · not yet recruiting
NCT07422948 — Efficacy and Safety of Early Initiation of Midodrine for Control and Prevention of Ascites and Its Related Complications · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04594954 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Institute of Liver and Biliary Sciences, India
Last refreshed: 16 February 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04594954.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing